CYTARABINE Safety Questions, CYTARABINE Answers
More Here>>Side Effects - FDA Reports 2006-2008
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y ZWelcome! Patientsville.com provides unique information about CYTARABINE. Our extensive database of CYTARABINE adverse events and CYTARABINE warnings is updated regularly. If you have questions, you can post them to one of our health experts or ask others in our broad patient community.
>> Announcements
Check out our Hospital and Home Care Quality Reports.
Ask Our Health Experts about CYTARABINE
CYTARABINE Safety Reports
Total CYTARABINE reports: 281.CYTARABINE FDA safety alerts: No.
Reported deaths: 61 Reported hospitalizations: 192.
Take CYTARABINE Side Effects Survey or Share Your CYTARABINE Story. CYTARABINE Usage.
Showing 1-75 of 281 Next >
Physician from UNITED STATES reported CYTARABINE problem on Apr 10, 2007. Female patient, 73 years of age, was diagnosed with myeloid leukaemia, neutropenia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia, hidradenitis. CYTARABINE dosage: unknown. During the same period patient was treated with NEUPOGEN, IDARUBICIN. Patient recovered.CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on Apr 30, 2007. Female patient, weighting 56.22 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: abdominal tenderness, antithrombin iii decreased, ascites, cardiac failure congestive, disseminated intravascular coagulation, ejection fraction decreased, fluid overload, hepatic failure, hypotension. CYTARABINE dosage: 7840 MG (980 MG IV Q12 HRS X 4 DAYS). During the same period patient was treated with MYLOTARG. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on Apr 30, 2007. Male patient, weighting 173.7 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: neutropenic sepsis, platelet count decreased, tachycardia, white blood cell count decreased. CYTARABINE dosage: 4000 MG. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on May 01, 2007. Male patient, weighting 145.1 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: haemothorax, post procedural haemorrhage. CYTARABINE dosage: 1218 MG. During the same period patient was treated with DAUNORUBICIN, MYLOTARG. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on May 04, 2007. Male patient, weighting 231.5 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: cerebral haemorrhage, dyspnoea, hyperhidrosis, malaise, pain. CYTARABINE dosage: 460 MG. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on May 04, 2007. Male patient, weighting 195.4 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: anaphylactic reaction, blood creatinine increased, blood urea increased, haemodialysis, haemoglobin decreased, mouth haemorrhage, obstructive airways disorder, oliguria. CYTARABINE dosage: 1400 MG. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on May 04, 2007. Male patient, weighting 195.4 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: carotid artery occlusion, cavernous sinus thrombosis, hypotension, iiird nerve paralysis, loss of consciousness, mass, mucormycosis, neutropenia. CYTARABINE dosage: 1400 MG. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on May 07, 2007. Male patient, weighting 145.1 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: haemothorax, pleural effusion, post procedural complication. CYTARABINE dosage: 1218 MG. During the same period patient was treated with DAUNORUBICIN, MYLOTARG. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on May 08, 2007. Male patient, weighting 155.3 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: back pain, loss of consciousness, neuropathy. CYTARABINE dosage: 680 MG. During the same period patient was treated with DEXAMETHASONE, ETOPOSIDE, VINCRISTINE SULPHATE. Patient was hospitalized. Patient died on 04/28/2007.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on May 15, 2007. Male patient, weighting 149.9 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: abdominal distension, abdominal pain, back pain, cardiac arrest, cyanosis, hypotension, hypoxia, intervertebral disc protrusion, intervertebral discitis. CYTARABINE dosage: 680 MG. During the same period patient was treated with DEXAMETHASONE, ETOPOSIDE, VINCRISTINE SULPHATE. Patient was hospitalized. Patient died on 04/29/2007.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on May 23, 2007. Female patient, weighting 256.4 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: acidosis, ammonia increased, aspergillosis, blood culture positive, brain oedema, caecitis, colitis, gastroenteritis escherichia coli, gastrointestinal necrosis. CYTARABINE dosage: 70 MG. During the same period patient was treated with DAUNORUBICIN, METHOTREXATE, PREDNISONE, VINCRISTINE SULPHATE, INSULIN, LAXATIVE, NEXIUM. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Health Professional from UNITED STATES on May 11, 2007. Female patient, 55 years of age, weighting 185.2 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: bone marrow failure, febrile neutropenia, immunosuppression. CYTARABINE dosage: unknown. During the same period patient was treated with MITOXANTRONE, ETOPOSIDE. Patient was hospitalized. Patient recovered.
Pharmacist from UNITED STATES reported CYTARABINE problem on May 24, 2007. Male patient, 48 years of age, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: pancytopenia, pyrexia. CYTARABINE dosage: unknown. During the same period patient was treated with FILGRASTIM. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on May 24, 2007. Female patient, weighting 158.3 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: torsade de pointes, ventricular fibrillation. CYTARABINE dosage: 177 MG. During the same period patient was treated with DAUNORUBICIN, MYLOTARG. Patient was hospitalized. Patient recovered.
Physician from FRANCE reported CYTARABINE problem on May 14, 2007. Female patient, 53 years of age, was diagnosed with meningeal disorder and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: aphasia, vasculitis cerebral. CYTARABINE dosage: 50 MG;X1;INTH. During the same period patient was treated with METHOTREXATE, CORTICOSTEROIDS. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Health Professional from JAPAN on May 23, 2007. Female patient, 61 years of age, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: blast cell count increased, cerebral haemorrhage. CYTARABINE dosage: unknown. During the same period patient was treated with IMATINIB MESYLATE. Patient died.
Health Professional from UNITED STATES reported CYTARABINE problem on May 16, 2007. Female patient, 65 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: cauda equina syndrome, decubitus ulcer, deep vein thrombosis, neurotoxicity, pneumonia cytomegaloviral. CYTARABINE dosage: unknown. During the same period patient was treated with METHOTREXATE, DEPOCYT, FRACTIONATED CYCLOPHOSPHAMIDE, VINCRISTINE, DOXORUBICIN. Patient recovered.
CYTARABINE problem was reported by a Health Professional from UNITED STATES on May 16, 2007. Female patient, 42 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: cauda equina syndrome, convulsion, faecal incontinence, hypoaesthesia, neurotoxicity, papilloedema, urinary hesitation. CYTARABINE dosage: unknown. During the same period patient was treated with METHOTREXATE, DEPOCYT, FRACTIONATED CYCLOPHOSPHAMIDE, VINCRISTINE, DOXORUBICIN, DEXAMETHASONE, NEUPOGEN, ANTIBIOTICS. Patient recovered.
Health Professional from UNITED STATES reported CYTARABINE problem on May 16, 2007. Female patient, 19 years of age, was diagnosed with b-cell type acute leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: benign intracranial hypertension, neurotoxicity, visual acuity reduced. CYTARABINE dosage: unknown. During the same period patient was treated with METHOTREXATE, DEPOCYT, FRACTIONATED CYCLOPHOSPHAMIDE, VINCRISTINE, DOXORUBICIN, DEXAMETHASONE. Patient recovered.
CYTARABINE problem was reported by a Health Professional from UNITED STATES on May 16, 2007. Male patient, 22 years of age, was diagnosed with b precursor type acute leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: complex partial seizures, convulsion, neurotoxicity. CYTARABINE dosage: unknown. During the same period patient was treated with METHOTREXATE, DEPOCYT, FRACTIONATED CYCLOPHOSPHAMIDE, VINCRISTINE, DOXORUBICIN, DEXAMETHASONE. Patient recovered.
Physician from UNITED STATES reported CYTARABINE problem on May 16, 2007. Male patient, 54 years of age, was diagnosed with b precursor type acute leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: encephalitis, neurotoxicity. CYTARABINE dosage: unknown. During the same period patient was treated with METHOTREXATE, DEPOCYT, VINCRISTINE, CYCLOPHOSPHAMIDE, DOXORUBICIN, DEXAMETHASONE, RITUXIMAB, NEUPOGEN. Patient died.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on May 14, 2007. Male patient, 42 years of age, weighting 140.0 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: abdominal pain, acute respiratory distress syndrome, acute respiratory failure, bacterial infection, blood creatinine increased, blood culture positive, blood ph decreased, blood urea decreased, clostridium difficile colitis. CYTARABINE dosage: unknown. During the same period patient was treated with MITOXANTRONE, ETOPOSIE. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on May 30, 2007. Male patient, weighting 182.1 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: escherichia sepsis, hypotension, neutropenia, respiratory failure. CYTARABINE dosage: 34740 MG. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Physician from CANADA on May 22, 2007. Female patient, child 7 years of age, was diagnosed with b precursor type acute leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: aphasia, brain oedema, cerebrovascular spasm, coagulopathy, encephalopathy, hallucination, visual, hemiparesis, incontinence, reversible posterior leukoencephalopathy syndrome. CYTARABINE dosage: 70 MG PER_CYCLE IT. During the same period patient was treated with DEXAMETHASONE, VINCRISTINE, METHOTREXATE. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on May 31, 2007. Male patient, weighting 176.4 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: dyspnoea exertional, haematocrit decreased, haemoglobin decreased, palpitations. CYTARABINE dosage: 35400 MG. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Physician from UNITED STATES on May 21, 2007. Male patient, child 11 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: metastases to lymph nodes, renal failure chronic. CYTARABINE dosage: 380 MG. During the same period patient was treated with ETOPOSIDE, DEXAMETHASONE, THIOGUANINE, DAUNORUBICIN. Patient died.
Consumer or non-health professional from UNITED KINGDOM reported CYTARABINE problem on May 25, 2007. Male patient, 36 years of age, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: acute myeloid leukaemia, multi-organ failure, neutropenic sepsis, no therapeutic response. CYTARABINE dosage: 2000 MG/M2 PER_CYCLE IV. During the same period patient was treated with FLUDARABINE PHOSPHATE, IDARUBICIN, NEUPOGEN. Patient died on 04/23/2007.
CYTARABINE problem was reported by a Physician from UNITED STATES on May 21, 2007. Male patient, child 11 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: metastases to lymph nodes, renal failure chronic. CYTARABINE dosage: 380 MG. During the same period patient was treated with ETOPOSIDE, DEXAMETHASONE, THIOGUANINE, DANORUBICIN. Patient died.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on June 05, 2007. Female patient, weighting 256.4 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: acidosis, ammonia increased, ascites, aspergillosis, biliary cirrhosis, brain oedema, caecitis, cerebral disorder, cholestasis. CYTARABINE dosage: 70 MG. During the same period patient was treated with DAUNORUBICIN, METHOTREXATE, PREDNISONE, VINCRISTINE SULPHATE, INSULIN, LAXATIVE, NEXIUM. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on June 08, 2007. Female patient, weighting 200.2 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: dizziness postural, dysarthria, headache. CYTARABINE dosage: 36000 MG. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on June 11, 2007. Male patient, weighting 183.4 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: aplasia, central line infection, staphylococcal infection. CYTARABINE dosage: 1400 MG. During the same period patient was treated with DAUNORUBICIN, MYLOTARG. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on June 14, 2007. Male patient, weighting 188.3 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: ascites, atelectasis, atrial fibrillation, blood culture positive, cholelithiasis, ejection fraction decreased, haemodialysis, hepatomegaly, hypotension. CYTARABINE dosage: 3760 MG. During the same period patient was treated with DEXAMETHASONE, IFOSFAMIDE, LEUCOVORIN CALCIUM, MESNA, METHOTREXATE, RITUXIMAB, VINCRISTINE SULPHATE. Patient was hospitalized. Patient recovered.
Health Professional from JAPAN reported CYTARABINE problem on June 13, 2007. Female patient, 61 years of age, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: blast cell count increased, cerebral haemorrhage. CYTARABINE dosage: unknown. During the same period patient was treated with IMATINIB MESYLATE. Patient died.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on June 22, 2007. Female patient, weighting 179.0 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: acute myeloid leukaemia, dehydration, demyelination, dry mouth, gait disturbance, hallucination, nausea, nuclear magnetic resonance imaging brain abnormal. CYTARABINE dosage: unknown. During the same period patient was treated with CELEXA. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on June 21, 2007. Female patient, weighting 85.76 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: aspergillosis, bacterial infection, brain herniation, brain scan abnormal, cerebral haemorrhage, cerebral infarction, facial nerve disorder, facial palsy, fungal infection. CYTARABINE dosage: 10000 MG. During the same period patient was treated with MYLOTARG, MITOXANTRONE. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Health Professional from UNITED STATES on June 18, 2007. Male patient, 76 years of age, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: bronchopneumonia, cardiopulmonary failure, haemoglobin decreased, platelet count decreased. CYTARABINE dosage: unknown. During the same period patient was treated with IMIPENEM, VANCOMYCIN, AMINOPHYLLIN, OXYGEN. Patient was hospitalized. Patient died.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on June 25, 2007. Male patient, weighting 44.53 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: blood albumin decreased, blood potassium increased, blood pressure decreased, bradycardia, cardiac arrest, escherichia infection, haematocrit decreased, haemoglobin decreased, lung infiltration. CYTARABINE dosage: 30048 MG. During the same period patient was treated with CYCLOPHOSPHAMIDE, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, MESNA. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Health Professional from UNITED STATES on June 20, 2007. Male patient, 64 years of age, weighting 187.2 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: dysphagia, febrile neutropenia, mucosal inflammation, oral pain, white blood cell count decreased. CYTARABINE dosage: unknown. During the same period patient was treated with MITOXANTRONE, ETOPOSIDE. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on June 26, 2007. Male patient, weighting 179.0 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: blood culture positive, pseudomonas infection. CYTARABINE dosage: 700 MG. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on June 26, 2007. Female patient, weighting 130.1 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: abdominal pain lower, anorexia, colitis, diarrhoea, disease recurrence, nausea, oral intake reduced, pyrexia. CYTARABINE dosage: unknown. During the same period patient was treated with DAUNORUBICIN. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on June 27, 2007. Female patient, weighting 129.2 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: atrial tachycardia, cellulitis, dysphagia, febrile neutropenia, herpes simplex, lip ulceration, pain, pharyngitis. CYTARABINE dosage: unknown. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on June 27, 2007. Male patient, weighting 143.3 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: blood phosphorus decreased, blood potassium decreased, hypotension, lobar pneumonia, mucosal inflammation, nausea, oral intake reduced, respiratory distress, sepsis. CYTARABINE dosage: unknown. During the same period patient was treated with DAUNORUBICIN, ETOPOSIDE. Patient died on 06/23/2007.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on June 27, 2007. Female patient, weighting 209.9 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: acidosis, apnoea, bacterial sepsis, cardiac arrest, cellulitis, disease progression, hypotension, pain, pancytopenia. CYTARABINE dosage: unknown. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from SERBIA AND MONTENEGRO on June 28, 2006. Male patient, 37 years of age, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: neutropenic colitis, thrombocytopenia. CYTARABINE dosage: 200 MG BID IV. During the same period patient was treated with VEPESID, ADRIBLASTINE. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on July 12, 2006. Male patient, 81 years of age, weighting 160.1 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: anorexia, aphagia, bacteraemia, blood alkaline phosphatase increased, blood culture positive, fatigue, febrile neutropenia, pancytopenia, stomatitis. CYTARABINE dosage: unknown. During the same period patient was treated with ETOPOSIDE, MITOXANTRONE, ACYCLOVIR, PREDTE. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Health Professional from UNITED STATES on July 07, 2006. Female patient, 53 years of age, weighting 152.4 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: blood pressure decreased, escherichia bacteraemia, hypotension. CYTARABINE dosage: unknown. During the same period patient was treated with ETOPOSIDE, MITOXANTRONE. Patient recovered.
Physician from UNITED STATES reported CYTARABINE problem on July 12, 2006. Male patient, 62 years of age, weighting 213.8 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia. CYTARABINE dosage: unknown. During the same period patient was treated with ETOPOSIDE, MITOXANTRONE. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on July 20, 2006. Female patient, weighting 87.08 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: lung infiltration, pneumonia, refusal of treatment by patient, respiratory failure. CYTARABINE dosage: 640 MG. During the same period patient was treated with DAUNORUBICIN, DEXAMETHASONE. Patient was hospitalized. Patient died on 06/17/2006.
Health Professional from UNITED STATES reported CYTARABINE problem on July 24, 2006. Female patient, weighting 117.1 lb, was treated with CYTARABINE. CYTARABINE dosage: 100 MG/M2/DAY IV 1-7. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient died.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on July 26, 2006. Male patient, weighting 172.0 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: abasia, agitation, capillary leak syndrome, cardiac failure, cardio-respiratory arrest, cough, dyspnoea, exercise tolerance decreased. CYTARABINE dosage: 1288 MG. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on July 31, 2006. Female patient, weighting 155.9 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: asthenia, balance disorder, fall, haematoma, loss of consciousness. CYTARABINE dosage: 945 MG. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient died on 07/27/2006.
CYTARABINE problem was reported by a Physician from UNITED STATES on July 19, 2006. Female patient, 31 years of age, weighting 179.9 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia, lymphocyte count decreased, platelet count decreased, white blood cell count decreased. CYTARABINE dosage: 2835 MG BID IV. During the same period patient was treated with MEDROXYPROGESTERONE ACETATE, MOXIFLOXACIN, ACYCLOVIR, PROCHLORPERAZINE MALEATE, VANCOMYCIN, CITALOPRAM HYDROBROMIDE. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported CYTARABINE problem on July 19, 2006. Female patient, 31 years of age, weighting 179.9 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: atelectasis, blood culture positive, disease recurrence, febrile neutropenia, staphylococcal infection. CYTARABINE dosage: 2835 MG BID IV. During the same period patient was treated with MEDROXYPROGESTERONE ACETATE, MOXIFLOXACIN, ACYCLOVIR, PROCHLORPERAZINE MALEATE, VANCOMYCIN, CITALORPAM HYDROBROMIDE, ITRACONAZOLE, ROCEPHIN. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Physician from UNITED STATES on July 24, 2006. Male patient, 62 years of age, weighting 213.8 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: febrile neutropenia. CYTARABINE dosage: unknown. During the same period patient was treated with ETOPOSIDE, MITOXANTRONE. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on July 06, 2005. Female patient, 56 years of age, was diagnosed with acute myeloid leukaemia recurrent and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: dizziness, escherichia infection, febrile neutropenia, nausea, vomiting, white blood cell count decreased. CYTARABINE dosage: unknown. During the same period patient was treated with ETOPOSIDE, MITOXANTRONE, LEVOFLOXACIN, VALTREX. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on Sept 13, 2005. Female patient, 33 years of age, was diagnosed with myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: confusional state, enterococcal infection, mental status changes, nuclear magnetic resonance imaging brain abnormal, pyrexia, unresponsive to stimuli. CYTARABINE dosage: unknown. Patient died on 08/19/2005.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on Aug 01, 2006. Male patient, weighting 265.0 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: central line infection, neutrophil count decreased, white blood cell count decreased. CYTARABINE dosage: unknown. During the same period patient was treated with ETOPOSIDE. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 07, 2006. Female patient, weighting 168.0 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: anorexia. CYTARABINE dosage: 31320 MG. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on Aug 09, 2006. Female patient, weighting 237.9 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: acute myeloid leukaemia, acute respiratory distress syndrome, blood pressure decreased, cardiac arrest, febrile neutropenia, oxygen saturation decreased, paraneoplastic syndrome, respiratory failure. CYTARABINE dosage: 1266 MG. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient died on 08/02/2006.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 14, 2006. Female patient, weighting 168.0 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: anorexia. CYTARABINE dosage: 31320 MG. Patient recovered.
Physician from UNITED STATES reported CYTARABINE problem on Aug 04, 2006. Male patient, 59 years of age, weighting 159.6 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: central line infection, febrile neutropenia, staphylococcal infection. CYTARABINE dosage: 1881 MG QD IV. During the same period patient was treated with MITOXANTRONE, ETOPOSIDE, VORICONAZOLE, ALLOPURINOL, NORFLOXACIN, DIPHENHYDRAMINE, ACETAMINOPHEN. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Physician from UNITED STATES on Aug 04, 2006. Male patient, 68 years of age, weighting 147.9 lb, was diagnosed with acute myeloid leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: enterococcal infection, hypernatraemia, mucosal inflammation, neutropenia, white blood cell count decreased. CYTARABINE dosage: unknown. During the same period patient was treated with MITOXANTRONE, ETOPOSIDE, AMBISOME, ZOSYN, VANCOMYCIN, VALTREX, DEXAMETHASONE. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on Aug 16, 2006. Male patient, weighting 163.1 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: blood bilirubin increased, blood calcium decreased, blood lactate dehydrogenase increased, calcium ionised decreased, haematocrit decreased, haemoglobin decreased, haemolytic anaemia. CYTARABINE dosage: 1080 MG. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 22, 2006. Female patient, weighting 179.9 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: activated partial thromboplastin time prolonged, aggression, alanine aminotransferase increased, amnesia, aspartate aminotransferase increased, blood bilirubin increased, constipation, depressed level of consciousness, dizziness. CYTARABINE dosage: 2310 MG. During the same period patient was treated with DAUNORUBICIN, DEXAMETHASONE, CYCLOPHOSPHAMIDE, MERCAPTOPURINE, METHOTREXATE, VINCRISTINE SULPHATE, BACTRIM. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported CYTARABINE problem on Aug 11, 2006. Male patient, 51 years of age, was diagnosed with leukaemia and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: disease progression, dyspnoea, hepatic failure, oxygen saturation decreased, pleural effusion. CYTARABINE dosage: unknown. Patient was hospitalized. Patient died on 07/27/2006.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 24, 2006. Male patient, weighting 233.7 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: gangrene, neutropenia, oedema genital, penile pain, penile swelling, penile ulceration, phimosis, post procedural cellulitis, scratch. CYTARABINE dosage: 1575 MG. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on Aug 30, 2006. Female patient, weighting 196.7 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: abscess, bone marrow failure, brain compression, brain herniation, cerebral disorder, haemorrhage, mental status changes, pyrexia, refusal of treatment by relative. CYTARABINE dosage: 1330 MG. During the same period patient was treated with DAUNORUBICIN, LEUKINE. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 31, 2006. Male patient, weighting 163.1 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: autoimmune disorder, blood bilirubin increased, blood calcium decreased, blood potassium decreased, calcium ionised decreased, diabetes insipidus, diarrhoea, haemolysis, haemolytic anaemia. CYTARABINE dosage: unknown. During the same period patient was treated with DAUNORUBICIN. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on Sept 01, 2006. Male patient, child 10 years of age, weighting 116.8 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: blood pressure immeasurable, cholecystitis, colitis, convulsion, depressed level of consciousness, disseminated intravascular coagulation, encephalopathy, fungal infection. CYTARABINE dosage: 70 MG. During the same period patient was treated with DAUNORUBICIN, DEXAMETHASONE, METHOTREXATE, VINCRISTINE SULPHATE. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on Sept 01, 2006. Female patient, weighting 33.07 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: diarrhoea haemorrhagic, pancreatitis acute, peripancreatic fluid collection, post procedural complication. CYTARABINE dosage: 800 MG. During the same period patient was treated with CYCLOPHOSPHAMIDE, MERCAPTOPURINE, METHOTREXATE, VINCRISTINE SULPHATE, ERWINIA ASPARAGINASE. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on Aug 23, 2006. Female patient, 58 years of age, was diagnosed with mantle cell lymphoma stage iv and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: cardiomegaly, deep vein thrombosis, electrocardiogram st-t change, embolism venous, haematocrit decreased, lobar pneumonia, platelet count decreased, pulmonary embolism, refusal of treatment by patient. CYTARABINE dosage: unknown. During the same period patient was treated with DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, VINCRISTINE, CYCLOPHOSPHAMIDE, RITUXIMAB. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on Sept 05, 2006. Male patient, weighting 150.8 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: escherichia infection, fatigue, nausea, neutropenia. CYTARABINE dosage: unknown. During the same period patient was treated with ETOPOSIDE. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported CYTARABINE problem on Aug 25, 2006. Male patient, 58 years of age, was diagnosed with chronic lymphocytic leukaemia transformation and was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: hypertension, retinal haemorrhage. CYTARABINE dosage: unknown. Patient was hospitalized. Patient recovered.
CYTARABINE problem was reported by a Consumer or non-health professional from UNITED STATES on Sept 06, 2006. Female patient, weighting 134.7 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: escherichia bacteraemia, infection, neutropenia. CYTARABINE dosage: unknown. During the same period patient was treated with ETOPOSIDE. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported CYTARABINE problem on Sept 07, 2006. Female patient, weighting 33.07 lb, was treated with CYTARABINE. After drug was administered, patient experienced the following problems/side effects: pancreatitis acute, peripancreatic fluid collection, post procedural complication. CYTARABINE dosage: 800 MG. During the same period patient was treated with MERCAPTOPURINE, METHOTREXATE, VINCRISTINE, CYCLOPHOSPHAMIDE. Patient was hospitalized. Patient recovered.
Showing 1-75 of 281 Next >
This
drug has an active FDA Safety Alert